51 related articles for article (PubMed ID: 38691208)
1. Dermaseptin B2 bioactive gene's potential for anticancer and anti-proliferative effect is linked to the regulation of the BAX/BBC3/AKT pathway.
Nasirabadi FK; Doosti A
Med Oncol; 2024 May; 41(6):162. PubMed ID: 38767753
[TBL] [Abstract][Full Text] [Related]
2. Structure-function relationships of tachyplesins and their analogues.
Iwanaga S; Muta T; Shigenaga T; Seki N; Kawano K; Katsu T; Kawabata S
Ciba Found Symp; 1994; 186():160-74; discussion 174-5. PubMed ID: 7768150
[TBL] [Abstract][Full Text] [Related]
3. pDNA-tachyplesin treatment stimulates the immune system and increases the probability of apoptosis in MC4-L2 tumor cells.
Mahmoudi-Filabadi F; Doosti A
Amino Acids; 2024 May; 56(1):34. PubMed ID: 38691208
[TBL] [Abstract][Full Text] [Related]
4. Tachyplesin induces apoptosis in non-small cell lung cancer cells and enhances the chemosensitivity of A549/DDP cells to cisplatin by activating Fas and necroptosis pathway.
Wu J; Chen X; Zhang J; Chen J; Wang Y; Wei T; Ma J; Li Y; Mo T; He Z; Zhang H
Chem Biol Drug Des; 2021 Apr; 97(4):809-820. PubMed ID: 33245189
[TBL] [Abstract][Full Text] [Related]
5. Effects of tachyplesin and n-sodium butyrate on proliferation and gene expression of human gastric adenocarcinoma cell line BGC-823.
Shi SL; Wang YY; Liang Y; Li QF
World J Gastroenterol; 2006 Mar; 12(11):1694-8. PubMed ID: 16586536
[TBL] [Abstract][Full Text] [Related]
6. RGD-Tachyplesin inhibits tumor growth.
Chen Y; Xu X; Hong S; Chen J; Liu N; Underhill CB; Creswell K; Zhang L
Cancer Res; 2001 Mar; 61(6):2434-8. PubMed ID: 11289111
[TBL] [Abstract][Full Text] [Related]
7. Effects of tachyplesin I on human U251 glioma stem cells.
Ding H; Jin G; Zhang L; Dai J; Dang J; Han Y
Mol Med Rep; 2015 Apr; 11(4):2953-8. PubMed ID: 25434611
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis-like death-inducing property of tachyplesin I in Escherichia coli.
Kwun MS; Lee DG
J Basic Microbiol; 2021 Sep; 61(9):795-807. PubMed ID: 34337763
[TBL] [Abstract][Full Text] [Related]
9. Autophagy and cancer drug resistance in dialogue: Pre-clinical and clinical evidence.
Qin Y; Ashrafizadeh M; Mongiardini V; Grimaldi B; Crea F; Rietdorf K; Győrffy B; Klionsky DJ; Ren J; Zhang W; Zhang X
Cancer Lett; 2023 Aug; 570():216307. PubMed ID: 37451426
[TBL] [Abstract][Full Text] [Related]
10. Nano-Biotechnology and Challenges of Drug Delivery System in Cancer Treatment Pathway: Review Article.
Asadipour E; Asgari M; Mousavi P; Piri-Gharaghie T; Ghajari G; Mirzaie A
Chem Biodivers; 2023 Jun; 20(6):e202201072. PubMed ID: 36857487
[TBL] [Abstract][Full Text] [Related]
11. Tachyplesin I and its derivatives: A pharmaco-chemical perspective on their antimicrobial and antitumor potential.
Lu S; Lin J; Jin J; Zhang L; Guan Y; Chen H; Wu Y; Zhang W; Luan X
Expert Opin Drug Discov; 2022 Dec; 17(12):1407-1423. PubMed ID: 36503335
[TBL] [Abstract][Full Text] [Related]
12. Cancer and apoptosis: The apoptotic activity of plant and marine natural products and their potential as targeted cancer therapeutics.
Chaudhry GE; Md Akim A; Sung YY; Sifzizul TMT
Front Pharmacol; 2022; 13():842376. PubMed ID: 36034846
[TBL] [Abstract][Full Text] [Related]
13. Nanocarriers: A Reliable Tool for the Delivery of Anticancer Drugs.
Sabit H; Abdel-Hakeem M; Shoala T; Abdel-Ghany S; Abdel-Latif MM; Almulhim J; Mansy M
Pharmaceutics; 2022 Jul; 14(8):. PubMed ID: 36015192
[TBL] [Abstract][Full Text] [Related]
14. Anti-cancer peptides: their current trends in the development of peptide-based therapy and anti-tumor drugs.
Lath A; Santal AR; Kaur N; Kumari P; Singh NP
Biotechnol Genet Eng Rev; 2023 Apr; 39(1):45-84. PubMed ID: 35699384
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
